Despite barriers of blood, brain and bureaucracy, intranasal insulin may emerge as a promising treatment for pathological memory loss
The newest chemical under investigation for managing Alzheimer’s disease (AD) is actually not new at all. Insulin, the therapeutic hormone all-too familiar to individuals with diabetes, has been around for decades. In fact December will mark 90 years since its discoverers earned the Nobel Prize in Physiology or Medicine for the extraction of insulin for clinical use. Yet to say that insulin has been under our noses all these years wouldn’t exactly be correct. Because if it had been under our noses, we might have sensed its neurologic benefits sooner.
The latest insulin therapy is not delivered via injection like its diabetes-treating counterparts, nor does it come in the form of a pill or a patch like the cholinesterase inhibitors often prescribed to patients with AD. Instead this novel therapeutic enters the body through the nose—the only entry point that gives insulin a chance of reaching the brain.
A large peptide molecule, insulin from the blood cannot float easily into the brain because the blood brain barrier (BBB), a sort of neuroprotective moat, prevents its transport. Fortified by cellular guards called tight junctions, the BBB rejects many pharmacologic hopefuls, allowing entrance only to certain types of substances. Namely small or lipophilic molecules can be administered orally (or via injection, or through the skin) and as long as the relevant chemicals end up in the blood stream, they can casually saunter across the BBB and act on the brain. Large and cumbersome, insulin does not have this luxury and must therefore take a more creative route across the moat.
The nose, conspicuous and sometimes even goofy, provides that creative route. Yet it’s a route that, for many years, researchers were hesitant to take.
“They would say things like, ‘Well, why would there be a blood brain barrier if all you had to do was put something in the nose and it would go to the brain?’” says William H. Frey II, Ph.D., Research Director at HealthPartners Center for Memory & Aging. As of 1989 Frey had been “in the Alzheimer’s deal” for over a decade. At that time he was conducting clinical trials of a neurotrophic factor (a therapeutic protein) to treat AD and, because of the seeming insurmountability of the BBB, the work had been less than fruitful. “It became clear to me that, once again, this neurotrophic factor was not getting effectively into the brain,” he says. So Frey decided to sleep on it. “I went to sleep and I had a dream. And this is how I discovered the intranasal method of getting around the blood brain barrier,” he says. “It had been known since the early 1900s that a number of different viruses that got into the nose would travel up the olfactory nerves and the trigeminal nerves—both of these are nerves that go directly from the nasal mucosa right into the brain. The idea that came to me in this dream in 1989 was: if bad things can do it, why can’t good things do it?”
When Frey revisited the idea upon waking, it registered as simultaneously intuitive and absurd—a logical fantasy like so many dreams.
The Latest Bing News on:
- About Your Total Pancreatectomyon January 6, 2021 at 4:01 pm
If you take insulin or another medication for diabetes ... You’ll receive oxygen through a thin tube called a nasal cannula that rests below your nose. A nurse will be monitoring your body temperature ...
- Tonix deal sets up use of intranasal drug in diabetes, obesityon January 5, 2021 at 8:15 am
Researchers linked the changes to improvements in lipid metabolism, glucose intolerance and insulin resistance. Subsequent research has tied intranasal oxytocin to positive effects on weight ...
- New Diabetes Technology: What to Expect in 2021on January 3, 2021 at 4:01 pm
For example, non-insulin using type 2s or general health ... following the Baqsimi nasal glucagon from Eli Lilly and the Gvoke rescue pen and prefilled syringe by Xeris Pharmaceuticals.
- Intranasal Insulin Enhanced Resting-state Functional Connectivity of Hippocampal Regions in Type 2 Diabeteson January 1, 2021 at 4:00 pm
Type 2 diabetes mellitus (T2DM) alters brain function and manifests as brain atrophy. Intranasal insulin has emerged as a promising intervention for treatment of cognitive impairment. We evaluated ...
- COVID-19 and Diabetes: Understanding the reasons for worst outcomeson January 1, 2021 at 5:52 am
Also Read - 'Game changer against Covid-19': Expert panel recommends phase 1 trial of Bharat Biotech's nasal vaccine Diabetes is a complex condition wherein the body's sensitivity to insulin is ...
- Covid 'long-haul' symptoms leave survivors in emotional limbo. It's a familiar pain.on December 30, 2020 at 2:17 am
But I received a double-armed IV flush of insulin and fluids ... Unfortunately, according to the nasal swab I got later that day, I did not, in fact, have the coronavirus. A week later, I was ...
- Climbing Stairs may Help Reduce Metabolic Complicationson December 30, 2020 at 1:22 am
The study explored the effects of brief stair climbing exercise during prolonged sitting on postprandial insulin, glucose, and free fatty acids responses. Two group of individuals - 12 young ...
- FDA Nod For First Generic Drug To Treat Severe Hypoglycemiaon December 29, 2020 at 6:08 am
While insulin lowers blood sugar levels by moving ... In July 2019, the FDA gave nod to the glucagon nasal powder Baqsimi from Eli Lilly to treat severe hypoglycaemia, which is normally treated ...
- Price controls, currency devaluation fuel drug shortages in Egypton December 25, 2020 at 4:00 pm
Products that have suffered recent shortages range from government-subsidized imported baby formula and insulin, to locally produced nasal drops and laxatives and hormonal drugs used to treat ...
- Early Intranasal Insulin Therapy Halts Progression of Neurodegenerationon December 25, 2020 at 4:00 pm
 The subjects were treated with either a placebo, or one of two doses (20–40 IU) of intranasal insulin. At the end of a 4-month protocol, memory and cognitive performance were assessed to ...
The Latest Google Headlines on:
The Latest Bing News on:
- Childhood Alzheimer’s: A Chester County boy and his family are seeking help against a burglar of innocence | Maria Panaritison January 25, 2021 at 2:26 pm
Two years ago, an elementary school psychologist told Marisa DiChiacchio something that she describes, to this day, as “crazy.” Marisa’s 9-year-old son, Connor, was, quite literally, losing his mind.
- First observation of the early association between proteins linked to Alzheimer's diseaseon January 25, 2021 at 10:19 am
During the pre-clinical stages of Alzheimer's disease, i.e. when subtle changes are taking place in the brain but no cognitive symptoms can be observed, the cortex presents a state of transient ...
- Alzheimer's Assoc. of Greater Cincinnati with resources to help during the pandemicon January 25, 2021 at 10:12 am
Alzheimer's Assoc. of Greater Cincinnati with resources to help during the pandemic ...
- Alzheimer’s Foundation offering college scholarship to high school seniorson January 25, 2021 at 9:50 am
The Alzheimer’ (AFA) is offering scholarships to college-bound high school seniors affected by Alzheimer’s disease of up to $5,000 as part of its annual Teens for Alzheimer’s ...
- Those with Alzheimer's, dementia struggling with pandemic isolationon January 25, 2021 at 9:37 am
People living with Alzeheimer's or dementia are finding the pandemic is placing an increased burden on their lives. Isolation brought on by the lack of social interaction is one of the causes.
- First observation of the early link between proteins linked to Alzheimer's diseaseon January 25, 2021 at 8:22 am
Study conducted by researchers from the GIGA CRC In vivo Imaging laboratory at ULiège demonstrates, for the first time in humans, how the first deposits of tau proteins in the brainstem are associated ...
- Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Diseaseon January 25, 2021 at 5:53 am
AL002 is the first product candidate targeting TREM2 in Phase 2 clinical developmentStudy will enroll early Alzheimer’s disease patients at up to ...
- Alzheimer’s Association offers virtual educational programson January 25, 2021 at 5:44 am
The Alzheimer’s Association Northwest Ohio Chapter will be presenting a variety of virtual educational programs to help the community and families impacted by the disease.
- The Alzheimer's Drugs Showing Early Promiseon January 22, 2021 at 3:08 pm
A small study has found that the experimental drug donanemab may slow cognitive decline in Alzheimer's patients. It joins others that show promise.
- Outreach is key when it comes to the Black community and Alzheimer'son January 22, 2021 at 11:43 am
According to the Alzheimer’s Prevention Initiative, Black people are more than twice as likely as white people to develop Alzheimer’s disease.